Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer
September 22 2020 - 8:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
it will host a virtual Key Opinion Leader (KOL) event on locally
advanced pancreatic cancer on Friday, October 2, 2020, at 11 a.m.
EDT.
Sarah Hoffe, M.D., will provide a review of the management of
patients with localized pancreatic cancer, including the current
clinical treatment paradigm and the use of stereotactic body
radiation therapy (SBRT). Dr. Hoffe is the Section Head of GI
Radiation Oncology and Senior Member at Moffitt Cancer Center.
The live audio webcast of the event will be accessible from the
Investors page of Galera’s
website, investors.galeratx.com. Individuals
can participate in an interactive Q&A session by submitting
pertinent questions via the webcast platform.
An archived version of the webcast will be available in the News
& Events section of the Investors page of Galera’s website for
60 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing a pipeline of
novel, proprietary therapeutics that have the potential to
transform radiotherapy in cancer. Galera’s lead product candidate
is avasopasem manganese (GC4419), a highly selective small molecule
superoxide dismutase (SOD) mimetic initially being developed for
the reduction of radiation-induced severe oral mucositis (SOM).
Avasopasem is being studied in the Phase 3 ROMAN trial for its
ability to reduce the incidence and severity of SOM induced by
radiotherapy in patients with locally advanced head and neck cancer
(HNC), its lead indication. It is also being studied in a Phase 2a
multi-center trial in Europe assessing the safety of avasopasem in
patients with HNC undergoing standard-of-care radiotherapy, a Phase
2a trial for its ability to reduce the incidence of esophagitis
induced by radiotherapy in patients with lung cancer, and a Phase 2
trial in hospitalized patients who are critically ill with
COVID-19; and avasopasem completed enrollment in a pilot Phase 1/2
trial in combination with stereotactic body radiation therapy
(SBRT) in patients with locally advanced pancreatic cancer. The FDA
granted Fast Track and Breakthrough Therapy designations to
avasopasem for the reduction of SOM induced by radiotherapy. Galera
is headquartered in Malvern, PA. For more information, please
visit www.galeratx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding upcoming events
and presentations. These forward-looking statements are based on
management’s current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause Galera’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, the following: Galera’s limited operating
history; anticipating continued losses for the foreseeable future;
needing substantial funding and the ability to raise capital;
Galera’s dependence on avasopasem manganese (GC4419); uncertainties
inherent in the conduct of clinical trials; difficulties or delays
enrolling patients in clinical trials; the FDA’s acceptance of data
from clinical trials outside the United States; undesirable side
effects from Galera’s product candidates; risks relating to the
regulatory approval process; failure to capitalize on more
profitable product candidates or indications; ability to receive
Breakthrough Therapy Designation or Fast Track Designation for
product candidates; failure to obtain regulatory approval of
product candidates in the United States or other jurisdictions;
ongoing regulatory obligations and continued regulatory review;
risks related to commercialization; risks related to competition;
ability to retain key employees and manage growth; risks related to
intellectual property; inability to maintain collaborations or the
failure of these collaborations; Galera’s reliance on third
parties; the possibility of system failures or security breaches;
liability related to the privacy of health information obtained
from clinical trials and product liability lawsuits; unfavorable
pricing regulations, third-party reimbursement practices or
healthcare reform initiatives; environmental, health and safety
laws and regulations; the impact of the COVID-19 pandemic on
Galera’s business and operations, including preclinical studies and
clinical trials, and general economic conditions; risks related to
ownership of Galera’s common stock; and significant costs as a
result of operating as a public company. These and other important
factors discussed under the caption “Risk Factors” in Galera’s
Quarterly Report on Form 10-Q for the quarterly period ended June
30, 2020 filed with the U.S. Securities and Exchange Commission
(SEC), Annual Report on Form 10-K for the year ended December 31,
2019 and Galera’s other filings with the SEC could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Galera as of the
date of this release, and Galera assumes no obligation to, and does
not intend to, update any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
Jennifer PorcelliSolebury
Trout646-378-2962jporcelli@soleburytrout.com
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024